Clinical Trials Recruiting near Bethesda, MD

2,084 clinical trials have a recruiting site within 25 miles of Bethesda, Maryland, according to ClinicalTrials.gov data processed October 15, 2026. The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Recruiting now

Studies enrolling near Bethesda

Showing 30 studies, nearest first.

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
- Observational
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
45 sites within 25 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
- Phase 3
- Ages 18 to 60 years
- Sex: Female
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
13 sites within 25 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
12 sites within 25 mi
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
11 sites within 25 mi
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
- Observational
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
6 sites within 25 mi
Biospecimen Procurement for Head and Neck Disorders
NCT03429036
- Observational
- Ages 3 to 120 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
6 sites within 25 mi
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
- Observational
- Ages Any age
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
5 sites within 25 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
- Observational
- Ages 40 to 75 years
- Sex: All
- Accepts healthy volunteers
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
5 sites within 25 mi
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
- Phase 3
- Ages 18 to 130 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
5 sites within 25 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT06876714
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
5 sites within 25 mi
Project: Every Child for Younger Patients With Cancer
NCT02402244
- Observational
- Ages Up to 25 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562
- Phase 3
- Ages 6 months to 21 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377
- Phase 2
- Ages Any age
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410
- Phase 3
- Ages 5 to 60 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157
- Phase 2
- Ages 366 days to 46 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
Natural History of Stroke: Cause and Development
NCT00009243
- Observational
- Ages 18 to 120 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
- Observational
- Ages Any age
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
- Observational
- Ages Any age
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085
- Phase 3
- Ages 365 days to 25 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165
- Phase 3
- Ages Up to 50 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393
- Phase 2
- Ages 18 to 59 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406
- Phase 2
- Ages 18 to 59 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
3 sites within 25 mi

Source: ClinicalTrials.gov, data processed October 15, 2026. Recruiting US sites filtered by distance and site status; summaries shortened.